Novel vaccination strategies against tuberculosis.

The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG (Bacillus Calmette-Guérin) vaccine. Novel vaccination strategies are urgently needed to arrest global transmission and prevent the uncontrolled development of multidrug-resistant forms of Mycobacterium tuberculosis. Over the last two decades, considerable progress has been made in the field of vaccine development with numerous innovative preclinical candidates and more than a dozen vaccines in clinical trials. These vaccines are developed either as boosters of the current BCG vaccine or as novel prime vaccines to replace BCG. Given the enormous prevalence of latent TB infection, vaccines that are protective on top of an already established infection remain a high priority and a significant scientific challenge. Here we discuss the current state of TB vaccine research and development, our understanding of the underlying immunology, and the requirements for an efficient TB vaccine.

[1]  Nancy Everhart.  Where are we going? Where have we been? , 2016, School Libraries Worldwide.

[2]  A. Philip.  Where Are We Going? Where Have We Been? , 2015 .

[3]  S. Kaufmann,et al.  Recent advances towards tuberculosis control: vaccines and biomarkers , 2014, Journal of internal medicine.

[4]  B. Eisele,et al.  The BCG replacement vaccine VPM1002: from drawing board to clinical trial , 2014, Expert review of vaccines.

[5]  G. Schoolnik,et al.  Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics , 2014, Proceedings of the National Academy of Sciences.

[6]  G. Schoolnik,et al.  ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination , 2013, PloS one.

[7]  Olga T. Schubert,et al.  A Small RNA Encoded in the Rv2660c Locus of Mycobacterium tuberculosis Is Induced during Starvation and Infection , 2013, PloS one.

[8]  P. Beverley.  Clinical trials: TB vaccine failure was predictable , 2013, Nature.

[9]  J. Hamid,et al.  A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity , 2013, Science Translational Medicine.

[10]  B. Gicquel,et al.  Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. , 2013, Vaccine.

[11]  Peter Aaby,et al.  A small jab - a big effect: nonspecific immunomodulation by vaccines. , 2013, Trends in immunology.

[12]  J. Christensen,et al.  Comparing Adjuvanted H28 and Modified Vaccinia Virus Ankara Expressing H28 in a Mouse and a Non-Human Primate Tuberculosis Model , 2013, PloS one.

[13]  M. Demoitié,et al.  Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. , 2013, American journal of respiratory and critical care medicine.

[14]  S. Kaufmann,et al.  Inflammation in tuberculosis: interactions, imbalances and interventions. , 2013, Current opinion in immunology.

[15]  P. Andersen,et al.  Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1− IL-2–Secreting Central Memory Cells , 2013, The Journal of Immunology.

[16]  M. Demoitié,et al.  Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. , 2013, Vaccine.

[17]  S. Bertholet,et al.  Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. , 2013, The Journal of infectious diseases.

[18]  S. Kaufmann.  Tuberculosis vaccines: time to think about the next generation. , 2013, Seminars in immunology.

[19]  G. Kaplan,et al.  Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. , 2013, The Journal of infectious diseases.

[20]  S. Kaufmann,et al.  The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis , 2013, Annals of the New York Academy of Sciences.

[21]  Robert J Wilkinson,et al.  The immune response in tuberculosis. , 2013, Annual review of immunology.

[22]  H. McShane,et al.  Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques , 2013, Clinical and Vaccine Immunology.

[23]  S. Kaufmann,et al.  Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. , 2013, Vaccine.

[24]  G. Schoolnik,et al.  An Unbiased Genome-Wide Mycobacterium tuberculosis Gene Expression Approach To Discover Antigens Targeted by Human T Cells Expressed during Pulmonary Infection , 2013, The Journal of Immunology.

[25]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[26]  S. Wirtz,et al.  The Mincle-Activating Adjuvant TDB Induces MyD88-Dependent Th1 and Th17 Responses through IL-1R Signaling , 2013, PloS one.

[27]  S. Lockhart,et al.  Safety and efficacy of MVA 85 A , a new tuberculosis vaccine , in infants previously vaccinated with BCG : a randomised , placebo-controlled phase 2 b trial , 2013 .

[28]  S. Kaufmann,et al.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines , 2012, Medical Microbiology and Immunology.

[29]  Q. Jin,et al.  A comprehensive proteomic analysis of Mycobacterium bovis bacillus Calmette-Guérin using high resolution Fourier transform mass spectrometry. , 2012, Journal of proteomics.

[30]  F. Ahmad,et al.  Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model. , 2012, Vaccine.

[31]  S. Kaufmann,et al.  Enabling biomarkers for tuberculosis control [State of the Art Series. New tools. Number 3 in the series]. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  T. Ottenhoff.  New pathways of protective and pathological host defense to mycobacteria. , 2012, Trends in microbiology.

[33]  A. Cooper,et al.  Protection versus pathology in tuberculosis: recent insights. , 2012, Current opinion in immunology.

[34]  J. Ernst.  The immunological life cycle of tuberculosis , 2012, Nature Reviews Immunology.

[35]  P. Andersen,et al.  Vaccine-Induced Th17 Cells Are Maintained Long-Term Postvaccination as a Distinct and Phenotypically Stable Memory Subset , 2012, Infection and Immunity.

[36]  F. Ahmad,et al.  Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung , 2012, PloS one.

[37]  S. Kaufmann.  Tuberculosis vaccine development: strength lies in tenacity. , 2012, Trends in immunology.

[38]  P. Andersen,et al.  The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity , 2012, PloS one.

[39]  S. Kaufmann,et al.  Mycobacterium tuberculosis: success through dormancy. , 2012, FEMS microbiology reviews.

[40]  M. Tameris,et al.  A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. , 2012, American journal of respiratory and critical care medicine.

[41]  A. Zychlinsky,et al.  Neutrophil function: from mechanisms to disease. , 2012, Annual review of immunology.

[42]  S. Kaufmann,et al.  Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? , 2012, Current opinion in microbiology.

[43]  D. Sherman,et al.  The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. , 2012, The Journal of clinical investigation.

[44]  K. Kupferschmidt.  Infectious disease. Taking a new shot at a TB vaccine. , 2011, Science.

[45]  J. Casanova,et al.  Genetic lessons learned from X‐linked Mendelian susceptibility to mycobacterial diseases , 2011, Annals of the New York Academy of Sciences.

[46]  G. Cheng,et al.  Vitamin D Is Required for IFN-γ–Mediated Antimicrobial Activity of Human Macrophages , 2011, Science Translational Medicine.

[47]  You-Ping Li,et al.  Mycobacterium vaccae as Adjuvant Therapy to Anti-Tuberculosis Chemotherapy in Never-Treated Tuberculosis Patients: A Meta-Analysis , 2011, PloS one.

[48]  S. Kaufmann.  Fact and fiction in tuberculosis vaccine research: 10 years later. , 2011, The Lancet. Infectious diseases.

[49]  J. Ernst,et al.  Suboptimal Activation of Antigen-Specific CD4+ Effector Cells Enables Persistence of M. tuberculosis In Vivo , 2011, PLoS pathogens.

[50]  S. Morris,et al.  Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. , 2011, Vaccine.

[51]  Sang-Nae Cho,et al.  The immunity and protective effects of antigen 85A and heat-shock protein X against progressive tuberculosis. , 2011, Microbes and infection.

[52]  M. Hatherill.  Prospects for elimination of childhood tuberculosis: the role of new vaccines , 2011, Archives of Disease in Childhood.

[53]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[54]  J. Drijfhout,et al.  Identification of Human T-Cell Responses to Mycobacterium tuberculosis Resuscitation-Promoting Factors in Long-Term Latently Infected Individuals , 2011, Clinical and Vaccine Immunology.

[55]  T. Scriba,et al.  Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. , 2010, Vaccine.

[56]  I. Orme.  The Achilles heel of BCG. , 2010, Tuberculosis.

[57]  M. Jenkins,et al.  Distinct functions of antigen-specific CD4 T cells during murine Mycobacterium tuberculosis infection , 2010, Proceedings of the National Academy of Sciences.

[58]  G. Kaplan,et al.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.

[59]  Sylvie Bertholet,et al.  A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis , 2010, Science Translational Medicine.

[60]  B. S. Srivastava,et al.  Comparative expression analysis of rpf-like genes of Mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions. , 2010, Microbiology.

[61]  J. Pedrosa,et al.  Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis , 2010, The Journal of experimental medicine.

[62]  D. Goletti,et al.  Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[63]  M. Tameris,et al.  The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. , 2010, American journal of respiratory and critical care medicine.

[64]  S. Kaufmann,et al.  New vaccines for tuberculosis , 2010, The Lancet.

[65]  T. Ottenhoff,et al.  Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers. , 2010, Vaccine.

[66]  C. F. von Reyn,et al.  Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine , 2010, AIDS.

[67]  M. Brennan,et al.  The second Geneva Consensus: Recommendations for novel live TB vaccines. , 2010, Vaccine.

[68]  W. Dixon,et al.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) , 2009, Annals of the rheumatic diseases.

[69]  S. Kaufmann.  The New Plagues: Pandemics and Poverty in a Globalized World , 2009 .

[70]  J. Flynn,et al.  The spectrum of latent tuberculosis: rethinking the biology and intervention strategies , 2009, Nature Reviews Microbiology.

[71]  M Elizabeth Halloran,et al.  Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics , 2009, Proceedings of the National Academy of Sciences.

[72]  J. Dietrich,et al.  Protection and Polyfunctional T Cells Induced by Ag85B-TB10.4/IC31® against Mycobacterium tuberculosis Is Highly Dependent on the Antigen Dose , 2009, PloS one.

[73]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[74]  P. Andersen,et al.  A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells , 2009, PloS one.

[75]  S. Kaufmann,et al.  Identification of T-Cell Antigens Specific for Latent Mycobacterium Tuberculosis Infection , 2009, PloS one.

[76]  A. Thomas,et al.  MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques , 2009, PloS one.

[77]  J. Christensen,et al.  CD4 and CD8 T Cell Responses to the M. tuberculosis Ag85B-TB10.4 Promoted by Adjuvanted Subunit, Adenovector or Heterologous Prime Boost Vaccination , 2009, PloS one.

[78]  I. Orme,et al.  Post-exposure vaccination against Mycobacterium tuberculosis. , 2009, Tuberculosis.

[79]  R. Coler,et al.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys , 2009, Proceedings of the National Academy of Sciences.

[80]  S. Morris,et al.  The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. , 2008, Vaccine.

[81]  A. Hill,et al.  Multifunctional, High-Level Cytokine-Producing Th1 Cells in the Lung, but Not Spleen, Correlate with Protection against Mycobacterium tuberculosis Aerosol Challenge in Mice , 2008, The Journal of Immunology.

[82]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[83]  Tige R. Rustad,et al.  The Enduring Hypoxic Response of Mycobacterium tuberculosis , 2008, PloS one.

[84]  R. Koup,et al.  Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations , 2007, European journal of immunology.

[85]  J. Kirman,et al.  Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis. , 2007, Tuberculosis.

[86]  K. Lingnau,et al.  IC31® and IC30, novel types of vaccine adjuvant based on peptide delivery systems , 2007, Expert review of vaccines.

[87]  D. Russell,et al.  Mycobacterium tuberculosis and the environment within the phagosome , 2007, Immunological reviews.

[88]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[89]  S. Kaufmann,et al.  Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis , 2007, Proceedings of the National Academy of Sciences.

[90]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[91]  T. van der Poll,et al.  Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon , 2007, Infection and Immunity.

[92]  M. Pai,et al.  The prognosis of latent tuberculosis: can disease be predicted? , 2007, Trends in molecular medicine.

[93]  R. Locksley,et al.  IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge , 2007, Nature Immunology.

[94]  J. Dietrich,et al.  Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection1 , 2007, The Journal of Immunology.

[95]  Dirk Repsilber,et al.  Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis , 2007, Journal of Molecular Medicine.

[96]  P. Andersen.  Vaccine strategies against latent tuberculosis infection. , 2007, Trends in microbiology.

[97]  HIV vaccine failure prompts Merck to halt trial , 2007, Nature.

[98]  A. Stryhn,et al.  Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosis , 2006, European journal of immunology.

[99]  R. Rappuoli,et al.  Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guérin Immunity1 , 2006, The Journal of Immunology.

[100]  M. Bonneville,et al.  Human Vγ9Vδ2 T cells : promising new leads for immunotherapy of infections and tumors , 2006 .

[101]  S. Kaufmann.  Envisioning future strategies for vaccination against tuberculosis , 2006, Nature Reviews Immunology.

[102]  S. Kaufmann,et al.  Progress in tuberculosis vaccine development. , 2006, Current opinion in immunology.

[103]  G. Schoolnik,et al.  Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. , 2006, Microbes and infection.

[104]  P. Cardona.  RUTI: a new chance to shorten the treatment of latent tuberculosis infection. , 2006, Tuberculosis.

[105]  E. Gormley,et al.  The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. , 2006, Vaccine.

[106]  P. Aaby,et al.  Bacillus Calmette-Guérin vaccination and infant mortality , 2006, Expert review of vaccines.

[107]  Sabine Ehrt,et al.  Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. , 2006, Microbes and infection.

[108]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[109]  C. Dye,et al.  The Development and Impact of Tuberculosis Vaccines , 2006, Cell.

[110]  T. Ottenhoff,et al.  Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis , 2006, Clinical and Vaccine Immunology.

[111]  S. Behar,et al.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity. , 2006, Critical reviews in immunology.

[112]  A. Ziegler,et al.  Deconfounding microarray analysis - independent measurements of cell type proportions used in a regression model to resolve tissue heterogeneity bias. , 2006, Methods of information in medicine.

[113]  S. Kaufmann,et al.  Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. , 2006, Immunity.

[114]  S. Kaufmann.  Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. , 2005, The New England journal of medicine.

[115]  S. Kaufmann,et al.  From bacteriology to immunology: the dualism of specificity , 2005, Nature Immunology.

[116]  P. Andersen,et al.  Vaccines for Tuberculosis: Novel Concepts and Recent Progress , 2005, Clinical Microbiology Reviews.

[117]  S. Kaufmann,et al.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.

[118]  Sha Jiang,et al.  Therapeutic effects of Ag85B and MPT64 DNA vaccines in a murine model of Mycobacterium tuberculosis infection. , 2005, Vaccine.

[119]  P. Andersen,et al.  The success and failure of BCG — implications for a novel tuberculosis vaccine , 2005, Nature Reviews Microbiology.

[120]  M. Brennan,et al.  New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. , 2005, Vaccine.

[121]  A. Stryhn,et al.  Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 1 , 2005, The Journal of Immunology.

[122]  W. Jacobs,et al.  Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. , 2005, Microbes and infection.

[123]  D. Elías,et al.  PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[124]  M. Horwitz.  Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. , 2005, Microbes and infection.

[125]  A. Thomas,et al.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. , 2005, Vaccine.

[126]  M. Pai,et al.  Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review , 2004 .

[127]  Z. Xing,et al.  Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.

[128]  H. Mollenkopf,et al.  Application of Mycobacterial Proteomics to Vaccine Design: Improved Protection by Mycobacterium bovis BCG Prime-Rv3407 DNA Boost Vaccination against Tuberculosis , 2004, Infection and Immunity.

[129]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[130]  H. Mollenkopf,et al.  Immune response to postprimary tuberculosis in mice: Mycobacterium tuberculosis and Miycobacterium bovis bacille Calmette-Guérin induce equal protection. , 2004, The Journal of infectious diseases.

[131]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[132]  R. Gie,et al.  Resistant Mycobacterium bovis Bacillus Calmette-Guérin disease: implications for management of Bacillus Calmette-Guérin Disease in human immunodeficiency virus-infected children. , 2004, The Pediatric infectious disease journal.

[133]  M. Gennaro,et al.  Effect of Growth State on Transcription Levels of Genes Encoding Major Secreted Antigens of Mycobacterium tuberculosis in the Mouse Lung , 2004, Infection and Immunity.

[134]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[135]  Michael B Brenner,et al.  CD1: antigen presentation and T cell function. , 2004, Annual review of immunology.

[136]  A. Kaprelyants,et al.  Proteins of the Rpf Family: Immune Cell Reactivity and Vaccination Efficacy against Tuberculosis in Mice , 2003, Infection and Immunity.

[137]  S. Kaufmann,et al.  Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis , 2003, Nature Medicine.

[138]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[139]  Martin Tompa,et al.  Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis , 2003, Molecular microbiology.

[140]  S. Cole,et al.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis , 2003, Nature Medicine.

[141]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[142]  I. Orme,et al.  Pulmonary Necrosis Resulting from DNA Vaccination against Tuberculosis , 2003, Infection and Immunity.

[143]  W. Schmidt,et al.  Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. , 2002, Vaccine.

[144]  S. Morris,et al.  DNA Immunization in a Mouse Model of Latent Tuberculosis: Effect of DNA Vaccination on Reactivation of Disease and on Reinfection with a Secondary Challenge , 2002, Infection and Immunity.

[145]  J. Betts,et al.  Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling , 2002, Molecular microbiology.

[146]  T. Eguale,et al.  Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients , 2002, Journal of Clinical Microbiology.

[147]  P. Garner,et al.  Mycobacterium vaccae immunotherapy for treating tuberculosis. , 2003, The Cochrane database of systematic reviews.

[148]  M. Palmer,et al.  The family of thiol-activated, cholesterol-binding cytolysins. , 2001, Toxicon : official journal of the International Society on Toxinology.

[149]  Joseph Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .

[150]  S. Kaufmann,et al.  Prospects for better tuberculosis vaccines. , 2001, The Lancet. Infectious diseases.

[151]  P. Andersen,et al.  Protection of Mice with a Tuberculosis Subunit Vaccine Based on a Fusion Protein of Antigen 85B and ESAT-6 , 2001, Infection and Immunity.

[152]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[153]  S. Reed,et al.  T Cell Expression Cloning of a Mycobacterium tuberculosis Gene Encoding a Protective Antigen Associated with the Early Control of Infection1 , 2000, The Journal of Immunology.

[154]  D. Portnoy,et al.  A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. , 2000, Science.

[155]  P. Andersen,et al.  Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT‐6 antigen , 2000, European journal of immunology.

[156]  P. Andersen,et al.  CD4+ T-Cell Subsets That Mediate Immunological Memory to Mycobacterium tuberculosis Infection in Mice , 2000, Infection and Immunity.

[157]  S. Reed,et al.  Cloning, Expression, and Immunological Evaluation of Two Putative Secreted Serine Protease Antigens ofMycobacterium tuberculosis , 1999, Infection and Immunity.

[158]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[159]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[160]  T. Ganz,et al.  An antimicrobial activity of cytolytic T cells mediated by granulysin. , 1998, Science.

[161]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[162]  P. Andersen.  The T cell response to secreted antigens of Mycobacterium tuberculosis. , 1994, Immunobiology.

[163]  P. Andersen,et al.  Specificity of a protective memory immune response against Mycobacterium tuberculosis , 1993, Infection and immunity.

[164]  W. Janaszek.  [Evaluation of thermostability of lyophilized BCG vaccines by using an accelerated thermal degradation test]. , 1991, Medycyna doswiadczalna i mikrobiologia.

[165]  L. Bermudez,et al.  Recombinant Granulocyte–Macrophage Colony‐Stimulating Factor Activates Human Macrophages to Inhibit Growth or Kill Mycobacterium avium Complex , 1990, Journal of leukocyte biology.

[166]  I. Orme.  Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. , 1988, Journal of immunology.

[167]  I. Orme,et al.  Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin. , 1984, Cellular immunology.

[168]  K. Tolderlund.  Preliminary report of laboratory investigations on the effect of light on BCG vaccine. , 1952, Acta pathologica et microbiologica Scandinavica. Supplementum.

[169]  A. Calmette.  La vaccination preventive contre la tuberculose par le "BCG" , 1927 .

[170]  A. Guttstadt.  Die Wirksamkeit des Koch’schen Heilmittels gegen Tuberkulose: Ergänzungsband. Die Wirksamkeit des Koch’schen Heilmittels gegen Tuberkulose , 1891 .